3,870 Shares in Cellebrite DI Ltd. (NASDAQ:CLBT) Acquired by Gen Wealth Partners Inc

Gen Wealth Partners Inc purchased a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,870 shares of the company’s stock, valued at approximately $85,000.

Several other large investors have also recently modified their holdings of CLBT. NewEdge Advisors LLC increased its holdings in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock valued at $86,000 after purchasing an additional 3,352 shares during the period. R Squared Ltd bought a new stake in shares of Cellebrite DI in the 4th quarter valued at about $100,000. Polen Capital Management LLC acquired a new stake in shares of Cellebrite DI in the fourth quarter valued at about $222,000. Victory Capital Management Inc. bought a new position in shares of Cellebrite DI during the fourth quarter worth about $234,000. Finally, HighTower Advisors LLC acquired a new position in shares of Cellebrite DI in the fourth quarter worth approximately $274,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Up 2.9 %

Shares of NASDAQ CLBT opened at $19.83 on Friday. The firm has a market cap of $4.75 billion, a PE ratio of -14.27, a P/E/G ratio of 4.27 and a beta of 1.44. The company’s fifty day simple moving average is $18.92 and its 200 day simple moving average is $20.24. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, equities analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on CLBT shares. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Lake Street Capital increased their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI currently has a consensus rating of “Buy” and a consensus price target of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.